Navigation Links
Nobel Prize-Winning Discovery
Date:12/20/2007

Biomedical Research Is a Winning Pursuit

WASHINGTON, Dec. 19 /PRNewswire-USNewswire/ -- The following release was issued by Frankie L. Trull President, Foundation for Biomedical Research:

Biomedical research the National Institutes of Health deemed "not worthy of pursuit" in 1980 earned Mario Capecchi a Nobel Prize last month.

Despite the early setback, the Harvard-educated genetics professor persisted toward his goal. Within four years, Capecchi filed another NIH grant proposal, this time armed with further evidence of what he had sought to prove, that something called gene targeting was possible in mammals.

The Institutes, in responding to Capecchi's new request, said, "We are glad that you didn't follow our advice."

A lot of people feel the same way. Twenty years after his breakthroughs at the University of Utah's School of Medicine, it is clear how far researchers' understanding of human disease has progressed.

Another researcher, Oliver Smithies, who was concurrently pursuing a similar mission at the University of North Carolina at Chapel Hill, shares the 2007 Nobel Prize in Physiology or Medicine. The prize also belongs to Martin J. Evans of Cardiff University in Wales, who demonstrated that genes from embryonic stem cells can be inherited.

Want to figure out what role a certain gene plays in susceptibility to cancer? Or what another gene has to do with aging? Due to Capecchi's work, genetic modifications in mice make it possible to render selected genes inactive, thereby providing information about their functions.

Genes linked with hereditary conditions can be deactivated, or turned "off," in "knock-out mice." Researchers are already capable of knocking out more than 10,000 genes. In case you're not counting, this means researchers are halfway to uncovering the function of every gene common among mammals.

Conversely -- and here's where it gets really interesting -- scientists can intentionally activate these genes. Want to test a developing treatment for anxiety disorders? Trying a new medicine intended to prevent heart disease? Now an animal model can be engineered to contain the DNA that codes for an anxiety disorder, or heart disease. These research rodents are called "knock-in mice." Literally, the disorder is turned "on."

These discoveries open up a new frontier of possibility, destroying flat-world theory. Research is now possible that never was before. Advanced animal models are the wind that makes the sailboat move. They accelerate and navigate the research. The implications for human health are enormous, clearly worthy of pursuit. Knock-out and knock-in mice have moved researchers into uncharted waters of possibility and promise.

Pathways of many hereditary conditions -- including obesity, high blood pressure and Parkinson's disease -- can be modeled and studied in a laboratory. Smithies and Evans recognized the potential of this discovery, using knock-out and knock-in mice to study cystic fibrosis.

This disorder devastates multiple organ systems in one out of every 3,700 babies born in the United States, shortening their life expectancy to 33 years. Ten million Americans carry the CF gene without ever experiencing its symptoms. But those who live with the disease have serious breathing difficulty, overproduction of mucus, intestinal blockage, liver damage and, finally, premature death.

Gene therapy, though in the early stages of research, aims to knock out human disorder-causing genes, among other functions. Eventually, this could mean knocking out cystic fibrosis and other inherited disorders.

Without Evans, Smithies and Capecchi, essential health studies could not proceed. These three researchers have blown the doors off laboratory expectations. Their accomplishments have earned them the Nobel Prize.

Countless others in the research community are employing these and other methods to seek cures and treatments for disorders and diseases. Many of these individuals will never be honored with ticker-tape parades and Nobel prizes. They are nonetheless heroes deserving of our deep gratitude.

It is a "thank you" owed by everyone who believes in the power and promise of biomedical research to advance human and animal health. If we truly treasure life, then it should be easy to value the research intended to preserve it. In my book, this noble venture is one that is always worthy of pursuit.

Frankie L. Trull is president of the Washington, D.C.-based Foundation for Biomedical Research, for which Mario Capecchi sits on the Board of Governors.


'/>"/>
SOURCE Foundation for Biomedical Research
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
2. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
4. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
5. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
6. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
7. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
8. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
9. FASgen Announces New Discovery for Treatment of Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)...  Cornerstone Pharmaceuticals, Inc., a privately held, clinical-stage, ... Phase I trials evaluating its lead compound, CPI-613, ... of the American Society of Hematology (ASH) in ... two datasets show encouraging efficacy and safety results ... T-cell non-Hodgkin,s lymphoma (T-cell NHL), respectively, supporting the ...
(Date:12/5/2016)... , Dec. 5, 2016  Pennsylvania Physician General Dr. ... Alcohol Programs Gary Tennis today filled prescriptions ... Minnich,s Pharmacy in York to ... by Dr. Levine as a prescription to acquire naloxone ... "It,s important to remember that any Pennsylvanian can walk ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... ... until January 15, 2017 to apply for a 2016/2017 California Casualty Thomas R. ... . Qualifying schools can receive up to $3,000. , The grant ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... in research and development, largely due to its potential for revolutionizing human disease ... (hMSCs) and human induced pluripotent stem cells (hiPSCs). , Both platforms have ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has ... the world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every ...
(Date:12/6/2016)... ... 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to SpinLife, ... freedom to people who need help getting around. For some, advancing age has led ... of rehabilitation after an illness or accident. There is a wide variety of scooters, ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
Breaking Medicine News(10 mins):